San Diego-based Axiom Biosciences, whose lead cell therapy produced positive early results in newborns with severe brain injury, announced its intention to pursue an initial public offering on the Main Board of The Stock Exchange of Hong Kong.
Axiom believes the move — expected to take place in 2027 — would position it as the first U.S. biotech company to pursue a primary listing in Hong Kong, “reflecting a broader shift in where the world’s most ambitious science finds the ecosystem to thrive.” According to the company, the Hong Kong market offers deep biotech expertise, a strong appetite for clinical-stage innovation and direct proximity to Axiom’s Asian partners. The company intends to pursue a secondary U.S. listing eventually.
“Some of the most important science in the world is being built in the United States, but the way it gets funded hasn’t kept pace,” said Dr. Remo Moomiaie-Qajar, Axiom’s founder and CEO.
Last week, Axiom announced positive phase 1 results for its investigational Wharton’s Jelly-derived mesenchymal stem cell (WJ-MSC) therapy for neonatal brain injury. The therapy, co-developed with South Korea-based Medinno, is being developed to treat intraventricular hemorrhage (IVH) and hypoxic-ischemic encephalopathy (HIE), two severe neurological conditions in newborns associated with high rates of mortality and long-term disability.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!